Company Profile

Madeleine Pharmaceuticals Inc
Profile last edited on: 10/12/2017      CAGE: 79DA7      UEI: NNNDGQCK6RV9

Business Identifier: Harnessing the bodies natural therapeutic qualities
Year Founded
2014
First Award
2016
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1200 John Q Hammons Drive Suite 500
Chanhassen, MN 55317
   (608) 960-3864
   info@madeleine-pharma.com
   www.madeleine-pharma.com
Location: Single
Congr. District: 03
County: Carver

Public Profile

Madeleine Pharmaceuticals, Inc. is a U.S. biotechnology company seeking to develop MP3167 (Vastiras®) as protein replacement therapy for the treatment of cardiorenal complications associated with acute (AHF) and chronic (CHF) heart failure. Vastiras® can be formulated for both in-patient and out-patient care. Madeleine Pharmaceuticals, Inc. has unencumbered access to the IP in Madeleine Pty Ltd., the original company formed in 2009 in Australia after being spun out of a leading biomedical company Hospira (former NYSE:HSP), now wholly owned by Pfizer Pharmaceuticals, Inc. (NYSE:PFE) by acquisition in 2015. Madeleine Pty Ltd. maintains an Australian presence for Madeleine Pharmaceuticals, Inc. with access to regional grants, research expertise and Asian markets among other benefits.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $3,927,919
Project Title: Development of a Novel Drug Treatment for Decompensated Heart Failure

Key People / Management

  Thomas R Geimer -- CEO

  Leigh Berryman

  Jean-Marie Houle -- Clinical Development Advisor

  Lawrence Mahan -- Chief Scientific Officer

Company News

There are no news available.